Pharmacokinetic and <i>In Vivo</i> Efficacy Studies of the Mycobactin Biosynthesis Inhibitor Salicyl-AMS in Mice

Shichun Lun, Haidan Guo, John Adamson, Justin S. Cisar, Tony D. Davis, Sivagami Sundaram Chavadi, J. David Warren, Luis E. N. Quadri, Derek S. Tan, William R. Bishai

Antimicrobial Agents and Chemotherapy · 2013 · 52 citations · 14 references

DOIFull text

Open access

Concepts

Abstract

Mycobactin biosynthesis in Mycobacterium tuberculosis facilitates iron acquisition, which is required for growth and virulence. The mycobactin biosynthesis inhibitor salicyl-AMS [5'-O-(N-salicylsulfamoyl)adenosine] inhibits M. tuberculosis growth in vitro under iron-limited conditions. Here, we conducted a single-dose pharmacokinetic study and a monotherapy study of salicyl-AMS with mice. Intraperitoneal injection yielded much better pharmacokinetic parameter values than oral administration did. Monotherapy of salicyl-AMS at 5.6 or 16.7 mg/kg significantly inhibited M. tuberculosis growth in the mouse lung, providing the first in vivo proof of concept for this novel antibacterial strategy.

References

14